Phase II Study to Evaluate the Efficacy of Necitumumab and Gemcitabine Combination Therapy in Advanced Biliary Tract Cancer with EGFR Amplification

Sugimori Makoto0 个研究点目标入组 18 人开始时间: 2023年7月27日最近更新: 2023年10月17日

试验速览

阶段: 2 期
状态: 招募中
发起方
入组人数: 18

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 18age old 至 ot applicable（—）
性别: All

入选标准

•Patients who fulfill all of the following conditions are eligible for this study.
•1) Patients with unresectable or recurrent biliary tract cancer diagnosed as biliary tract cancer by pathological diagnosis (cytological or histological diagnosis).
•2) Patients must be at least 18 years of age.
•3) Patients have a cancer genome profiling test that indicates EGFR amplification.
•4) Patient is refractory to first-line therapy including gemcitabine.
•5) The patient is refractory or intolerant to treatment with a companion diagnostic agent, pembrolizumab, if the cancer genome profiling test results in TMB-H or MSI-H.
•6) The patient has measurable disease according to RECIST guideline Version 1.1.
•7) ECOG Performance Status is 0 or 1.
•8) No history of blood transfusion or G-CSF administration within 7 days prior to the examination, and no major abnormal findings in the latest laboratory values within 7 days prior to enrollment (laboratory values obtained on the same day of blood transfusion or G-CSF administration are acceptable).
•1. Neutrophil count 1500 per mm3 or higher
•2. Hemoglobin 8.0 g/dL or more
•3. Platelet count 100,000 per mm3 or higher
•4. Total bilirubin less than or equal to 1.5 mg /dL
•5. AST (GOT) less than or equal to 100 IU/L ( less than or equal to 200 IU /L in case of liver metastasis)
•6. ALT (GPT) less than or equal to 100 IU/L ( less than or equal to 200 IU /L for liver metastasis)
•7. Serum creatinine less than 1.5 mg /dL.
•If serum creatinine exceed 1.5 mg/dL, the patient is eligible if the creatinine clearance (CCr)*1 exceeds 40 mL/min.
•*: Measured CCr by 24-hour urine collection or calculated using the Cockcroft-Gault estimation formula.
•Men CCr = (140 - age) x weight (kg) / 72 / serum creatinine level (mg /dL)
•Women CCr = 0.85 x (140 - age) x body weight (kg) / 72 / serum creatinine level (mg /dL)
•9) Written consent is obtained from the patient after sufficient explanation of the study contents.
•10) Treatment is possible on an outpatient basis.

排除标准

•1) Cancer genome profiling was performed, and the RAS (RAS, RAF, MEK, ERK, MAP2K) pathway, PI3K pathway (PIK3CA, AKT, PIK3R1, PTEN, TSC1, TSC2, MTOR), which is downstream of EGFR, ERBB2, Pathological genetic alterations of ERBB2, ERBB3, and ERBB4, which belong to the same family as EGFR, pathological mutations of EGFR itself, FGFR2 fusion genes for which companion drugs exist, and fusion genes of NTRK1, NTRK2, and NTRK3 have been pointed out.
•2) Patient is intolerant of primary therapy including gemcitabine.
•3) Patients have been treated with anti-EGFR antibody drugs.
•4) Patients with metastasis to the central nervous system (brain, spinal cord, meninges) with symptoms.
•5) Patients with active multiple cancers.
•6) Patient has a local infection or active systemic infection requiring treatment.
•7) Have a clinically problematic psychiatric disorder that would preclude enrollment in the study.
•8) Patients with interstitial pneumonia/pulmonary fibrosis, unstable angina (angina with onset or worsening within the last 3 weeks), myocardial infarction within the last 6 months, untreated and uncontrolled thrombosis (deep vein thrombosis, pulmonary artery thrombosis, etc.), or other complications deemed serious by the treating physician.
•9) HBs antigen positive.
•10) HBs antigen negative but HBc antibody positive and/or HBs antibody positive, and HBV-DNA real-time PCR quantification method is 20 IU/mL (1.3 LogIU/mL) or more.
•11) Patients with diabetes mellitus uncontrolled by medication (fasting blood glucose level of 130 mg/dL or higher).
•12) Patients who are pregnant, may become pregnant, or wish to become pregnant during the treatment period.
•13) Patients who have participated in a clinical trial or clinical study of a drug or medical device at the same time as this study or within 30 days prior to enrollment in this study.
•14) Patients who have received any of the following treatments within the prescribed time period prior to enrollment in the study.
•1. The last administration of a cytotoxic anticancer drug within 2 weeks prior to enrollment.
•2. Received prior therapy (chemotherapy, molecular targeted therapy, antibody therapy, hormone therapy, immunotherapy, or radiation therapy) within 2 weeks prior to enrollment.
•3. Underwent major surgery (minor surgery such as lymph node biopsy, needle biopsy, port placement, etc. are not applicable) within 2 weeks prior to enrollment.
•15) Patients who have undergone major surgery (minor surgery such as lymph node biopsy, needle biopsy, port placement, etc. is not applicable) within 2 weeks prior to enrollment.

研究者

发起方

Sugimori Makoto

相似试验

已完成

2 期

A phase II study to investigate the efficacy of neoadjuvant erlotinib in patients with clinical stage I/II non-small cell lung cancer (NSCLC)early stage lung cancernon-small cell lung cancer stage I/II10038666

NL-OMON29708Antoni van Leeuwenhoek Ziekenhuis55

招募中

不适用

Phase 1B Study to assess safety and efficacy of Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy (NABUCCO)

NL-OMON55844Antoni van Leeuwenhoek Ziekenhuis54

进行中（未招募）

1 期

Multinational, multicenter, phase 2 study of the efficacy and safety of ABY-035 in treating and preventing relapse/recurrence of disease activity in subjects with non-infectious intermediate, posterior or pan-uveitis.non-infectious intermediate, posterior, or pan-uveitisMedDRA version: 20.0Level: PTClassification code 10046851Term: UveitisSystem Organ Class: 10015919 - Eye disorders

EUCTR2020-004964-25-ITAffibody AB110

进行中（未招募）

1 期

EUCTR2020-004964-25-ESAffibody AB110

进行中（未招募）

1 期

EUCTR2020-004964-25-DEAffibody AB20